Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
News|Articles|October 11, 2026
GI Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2026
Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Check out this September recap of OncLive’s coverage of the top news and expert insights in gastrointestinal cancers.
Advertisement
Advertisement
September 2026 brought a new FDA approval in cholangiocarcinoma, the withdrawal of an accelerated approval in colorectal cancer, several regulatory actions in neuroendocrine tumors, and updates in pancreatic and liver cancers, along with expert perspectives on neoadjuvant immunotherapy.
Related to this article
The top 5 OncLive TV videos of the week.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Japan approved Optune Pax plus gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
Advertisement
Advertisement